04 September 2019
Visiongain has launched a new pharma report Acute Repetitive Seizures Market Forecast : By Product (USL-261, NRL-1, AZ-002, Diastat Rectal Gel), By Region and Segment Forecasts.
The global Acute Repetitive Seizures market is poised for rapid growth between 2019 and 2029. High unmet medical clinical for patients, as well as caregivers and the availability of an advanced product pipeline are some of the main factors that should favor market growth. Drug therapy is effective for most patients with cluster convulsions. However, there are a significant number of therapeutic challenges and unmet medical needs including drug-induced seizures, adverse reactions and a lack of anti-epileptic agents that can prevent the development of convulsions and its comorbidities.
The market is currently driven by generic drugs that mainly include oral benzodiazepines (diazepam and lorazepam). Rectal diazepam is the only drug approved for use in the United States and buccal midazolam in the European Union. Other drugs, such as diazepam (oral and intramuscular), midazolam (oral, intranasal, intramuscular), lorazepam (oral, intranasal, sublingual) and progesterone are mainly used off label. The market should be consolidated with a few large companies and high market shares.
Leading companies featured in the report include UCB S.A. Belgium, Neurelis, Valeant Pharmaceuticals North America LLC., Alexza Pharmaceuticals, VERITON PHARMA and others
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The pharma wholesale and distribution market was valued at US$511.80 billion in 2021 and is projected to grow at a CAGR of 7.84% during the forecast period 2022-2032.
29 September 2022
The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.
21 September 2022
The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.
16 September 2022
The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.